US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Summary
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters
Description from Reuters.
Who is covering this
-
FDA declined to approve Summit Therapeutics' lung cancer drug
The agency said ivonescimab lacks a statistically significant overall survival benefit; Summit said it will continue development
-
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters





Comments
Comments need JavaScript.